Skip to content

ADAPT Study: Assessing Diet, Appetite and Physiology Throughout Weight Loss Study)

Physiological Changes Underlying the Weight Loss Plateau in Human

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06174389
Enrollment
90
Registered
2023-12-18
Start date
2023-10-01
Completion date
2027-07-31
Last updated
2025-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Keywords

Gloisis, Weight Change

Brief summary

Behavioral weight loss programs for obesity can result in weight loss and health benefits. However, behavioral weight loss often stops despite efforts to continue losing weight, this can be called an involuntarily weight loss plateau. This study investigates changes in metabolism and/or the brain that contribute to the occurrence of an involuntary weight loss plateau.

Detailed description

Participants will be asked to enroll for 18-months. Each participant will complete 3 in-person study visits, then participate an a 6-month weight loss program delivered remotely. Some participants may be invited to complete 3 additional in-person visits. Study Visit activities include questionnaires, blood draws, brain MRIs, body measurement and dual energy x-ray absorptiometry (DXA) scan for body composition measurement, a breathing test, and biopsies of muscle and fat tissue. Each participant will be provided a fitness tracker and body weight scale to use throughout the study.

Interventions

Behavioral Weight Loss Program is a modified version of the Diabetes Prevention Program.

Sponsors

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
CollaboratorNIH
University of Washington
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* BMI 30.0 - 50.0 kg/m2 * Able to attend study intervention classes and study visits/assessments * Independently living with access to food preparation facilities

Exclusion criteria

* Current smoker or regular use of nicotine containing products and/or cannabis * Heavy alcohol use (≥2 drinks/d for females, ≥3 drinks/d for males) or drug use * Known cognitive impairments or h/o stroke * Type 2 diabetes (known diagnosis or by screening A1c (≥6.5%)) * Medical conditions (chronic diseases, cancer, MS) or labs limiting ability to participate * Females: currently pregnant (or 6-months postpartum of full-term pregnancy) and/or current breastfeeding * Use of medications with significant effects on appetite (e.g., weight loss medications, atypical antipsychotics, stimulants) and/or chronic use of anticoagulants * History of bariatric surgery * History of eating disorder * Current participation in a formal weight loss program * Prior or current participation in a research study involving weight loss * Weight-reduced by \>10% within past year * Weight \> 330 pounds (MRI limit) * Allergy or intolerance to or unwillingness to consume study foods provided at visit * MRI contraindication (e.g., implanted metal, claustrophobia) * Do not have a phone compatible with activity tracker or access to videoconferencing platform that will be used for the dietary intervention or other appropriate technology needed to complete study procedures * Any condition(s) found by the study team and confirmed with the PI(s) that make it unsafe to participate

Design outcomes

Primary

MeasureTime frameDescription
Change in maximal respiratory capacity (oxygen consumption rate) in peripheral blood mononuclear cellsFrom baseline to active weight loss (at least 21 days of weight loss equivalent or greater than 0.5 pounds per week) and from baseline to weight loss plateau (after active weight loss, at least 21 days of halted weight loss, or +/- 0.25 pounds/week).Mitochondrial maximal respiratory capacity will be measured in fasting samples from peripheral blood mononuclear cells.
Change in fMRI BOLD signalFrom baseline to a weight loss plateau (after active weight loss, at least 21 days of halted weight loss, or +/- 0.25 pounds/week).fMRI BOLD signal to visual food cues within a priori brain regions of interest pre and post consuming a standardized meal. Meal-induced change will be calculated by post-pre meal BOLD signal.
Entry into involuntary weight loss plateauthroughout 18-month enrollmentbinary outcome (Y/N) and time from baseline

Countries

United States

Contacts

Primary ContactADAPT Study
uwadaptstudy@uw.edu206-616-6360
Backup ContactADAPT Study
uwadaptstudy@uw.edu206-685-1532

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026